Navigation Links
Panacea Pharmaceuticals Presents Three Papers Regarding Its Nanoparticle-Based Therapeutic Cancer Vaccine at the Society for Immunotherapy of Cancer Annual Meeting at National Harbor, MD
Date:11/8/2013

GAITHERSBURG, Md., Nov. 8, 2013 /PRNewswire-iReach/ -- Panacea Pharmaceuticals, Inc. presents three papers regarding its Nanoparticle-Based Therapeutic Cancer Vaccine at the Society for Immunotherapy of Cancer Annual Meeting at National Harbor, MD held November 8-10, 2013.  The three papers are titled:

Design, Development and Production of Nano-Particle-Based Anticancer Vaccine Targeting Human Aspartyl (Asparaginyl) β-Hydroxylase (HAAH)

Immunogenicity of a Lambda Phage-Based Anti-Cancer Vaccine Targeting HAAH

Inhibition of Tumor Growth in vivo by a Nanoparticle-Based Therapeutic Cancer Vaccine Targeting HAAH

(Photo: http://photos.prnewswire.com/prnh/20131108/MN13284)

Panacea has chosen to target the HAAH molecule for its proprietary therapeutic cancer vaccine because HAAH is expressed on cancer cells and not on non-cancer cells and its function is consistent with the etiology of cancer, i.e., is associated with growth, motility and invasiveness of cancer cells.  Monoclonal antibodies to HAAH have proven to have efficacy in both in vitro and in vivo tumor models.  HAAH is, however, an embryonic antigen, and as such, presents self-antigen tolerance.  The present vaccine entity is designed to overcome this tolerance by altering the presentation of the antigen and by providing an immunostimulant.  The nanoparticle is neutralized bacteriophage construct containing portions of HAAH, is easy to produce and is generally regarded as safe.  The nanoparticle vaccine carries 200-300 copies of HAAH fragments of approximately 25 kDa molecular weight on its surface.  The nanoparticle vaccine also contains DNA fragments that present the phage CpG motif to activate the MHC class II pathway.  We have engineered and manufactured the nanoparticle vaccine to meet FDA requirements for human use.

The nanoparticle therapeutic cancer vaccine targeting HAAH is clearly immunogenic in mice despite the high degree of homology to the human protein that makes the AAH resemble a self-antigen.  All three HAAH-lambda constructs were immunogenic and the antibody response was dose-dependent.  The nanoparticle therapeutic cancer vaccine targeting HAAH is effective in inhibition of tumor growth in mice under various conditions.  Each of the three constructs can inhibit tumor growth.  The vaccine can slow the growth of tumors prophylactically or by treatment simultaneous with or subsequent to establishment of solid tumors.

"We are excited to report that the nanoparticle-based therapeutic cancer vaccine targeting HAAH can be manufactured readily and is effective in tumor models", said Hossein Ghanbari, Ph.D., CEO and CSO of Panacea.  "The HAAH phage constructs are now being developed as clinical candidate vaccines and we are taking all the steps to prepare for an IND submission to FDA", said Steven Fuller, Ph.D., COO of Panacea.

Media Contact: Hossein Ghanbari, Panacea Pharmaceuticals, Inc., 240-305-4601, hag@panaceapharma.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Panacea Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2013 Financial Results
2. ANI Pharmaceuticals Reports Net Revenues of $7.8 million, adjusted Non-GAAP EBITDA of $1.7 Million, and EPS of $0.13 for the Third Quarter Ended September 30, 2013
3. Vanda Pharmaceuticals Reports Third Quarter 2013 Results
4. Questcor Pharmaceuticals to Present at the 2013 Credit Suisse Annual Healthcare Conference
5. Imprimis Pharmaceuticals Inc. Announces Shift in Strategic Direction
6. Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2013 Financial Results
7. Cadence Pharmaceuticals Reports Third Quarter 2013 Financial Results
8. AcelRx Pharmaceuticals Reports Third Quarter 2013 Financial Results
9. Cumberland Pharmaceuticals Reports Third Quarter Financial Results
10. Jazz Pharmaceuticals Announces Third Quarter 2013 Financial Results
11. Top Trial Firm Cohen, Placitella & Roth, PC Investigating Ariad Pharmaceuticals, Inc., for Suspending Sales of its Leukemia Drug Iclusig
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... Summary This report provides all the ... partnering interests and activities since 2010. Description The Partnering ... into the partnering activity of one of the world,s leading ... prepared upon purchase to ensure inclusion of the most up ... will be delivered in PDF format within 1 working day ...
(Date:3/27/2017)... 27, 2017  Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Cryoport" ... offer shares of common stock in an underwritten public ... with the Securities and Exchange Commission (the "SEC"). The ... there can be no assurance as to whether or ... the actual size or terms of the offering. Cryoport ...
(Date:3/27/2017)... Calif. , March 27, 2017  Sanderling ... acquired by Ethicon, a division of Johnson & ... System for the treatment of gastro-esophageal reflux disease ... sphincter augmentation (MSA) technology and the procedure is ... centers. Torax Medical was founded by ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... The Radiology Business ... has begun to serve as its new executive director. Mr. Still was selected through ... Committee. , “Bob, as he is known to our members, has been a ...
(Date:3/28/2017)... , ... March 28, 2017 , ... With less than ... acne, access to quality care can be limited while the desire to conquer breakouts ... customized prescription acne care for every customer online, today released its inaugural survey on ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... patients desire to achieve the “perfect smile.” The National Association of Dental Laboratories ... as what dentists should be aware of when utilizing dental laboratories and technicians ...
(Date:3/28/2017)... ... March 28, 2017 , ... With expansion and efficiency in mind, Patten Seed ... The seed processing plant opened in Marshallville in 2006, and a bagging and shipping ... opportunity for transition of Patten Seed operations to the Middle Georgia location from their ...
(Date:3/28/2017)... ... ... that reveals the mystery of Kevin’s purpose. “A Prophets Bones” is the creation of published ... him that he had neglected to do, but this was from God and there was ... would have felt themselves to be special and better than others due to the fact ...
Breaking Medicine News(10 mins):